Abstract:Mitochondrial drug delivery has attracted increasing attention in various mitochondrial dysfunction-associated disorders such as cancer owing to the important role of energy production. Herein, we report a lysosomal pH-activated mitochondrial-targeting polymer nanoparticle to overcome drug resistance by a synergy between mitochondrial delivery of doxorubicin (DOX, an anticancer drug) and erlotinib-mediated inhibition of drug efflux. The obtained nanoparticles, DE-NPs could maintain negative charge and have long blood circulation while undergoing charge reversal at lysosomal pH after internalization by cancer cells. Thereafter, the acidity-activated polycationic and hydrophobic polypeptide domains boost lysosomal escape and mitochondrial-targeting drug delivery, leading to mitochondrial dysfunction, ATP suppression, and cell apoptosis. Moreover, the suppressed ATP supply and erlotinib enabled dual inhibition of drug efflux by DOX-resistant MCF-7/ADR cells, leading to significantly augmented intracellular DOX accumulation and a synergistic anticancer effect with a 17-fold decrease of IC50 relative to DOX. In vivo antitumor study demonstrates that DE-NPs efficiently suppressed the tumor burden in MCF-7/ADR tumor-bearing mice and led to negligible toxicity. This work establishes that a combination of mitochondrial drug delivery and drug efflux inhibition could be a promising strategy for combating multidrug resistance.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.1c03196?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.1c03196</a>.Synthetic scheme of PKCF; 1H NMR and FTIR spectra of polymers; DLS and zeta potentials of PKCF and D-NPs; cytotoxicity of PKCF NPs; cytotoxicity of Erlo and NPs against MCF-7 cells; cellular uptake of different formulations; cell cycle analysis; and H&E staining images of organs after treatment (<a class="ext-link" href="/doi/suppl/10.1021/acsami.1c03196/suppl_file/am1c03196_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Tumor-Penetrating and Mitochondria-Targeted Drug Delivery Overcomes Doxorubicin Resistance in Lung Cancer

Tumor acidity activated triphenylphosphonium-based mitochondrial targeting nanocarriers for overcoming drug resistance of cancer therapy

Mitochondria and Nucleus Dual Delivery System to Overcome DOX Resistance

Trackable Mitochondria-Targeting Nanomicellar Loaded with Doxorubicin for Overcoming Drug Resistance

Mitochondrial Targeted Doxorubicin Derivatives Delivered by ROS-responsive Nanocarriers to Breast Tumor for Overcoming of Multidrug Resistance.

Light-responsive nanodrugs co-self-assembled from a PEG-Pt(iv) prodrug and doxorubicin for reversing multidrug resistance in the chemotherapy process of hypoxic solid tumors

Reversal of Doxorubicin Resistance in Breast Cancer by Mitochondria-Targeted Ph-Responsive Micelles.

Co-delivery of DOX and PDTC by Ph-Sensitive Nanoparticles to Overcome Multidrug Resistance in Breast Cancer.

Tumor-homing, Ph- and Ultrasound-Responsive Polypeptide-Doxorubicin Nanoconjugates Overcome Doxorubicin Resistance in Cancer Therapy

Folate-mediated mitochondrial targeting with doxorubicin-polyrotaxane nanoparticles overcomes multidrug resistance

Mitochondrial-Targeting Lonidamine-Doxorubicin Nanoparticles for Synergistic Chemotherapy to Conquer Drug Resistance.

Overcoming Chemotherapy Resistance Via Simultaneous Drug-Efflux Circumvention and Mitochondrial Targeting

An energy-blocking nanoparticle decorated with anti-VEGF antibody to reverse chemotherapeutic drug resistance

Doxorubicin Hydrochloride and L-arginine Co-Loaded Nanovesicle for Drug Resistance Reversal Stimulated by Near-Infrared Light

Mitochondria-targeting polydopamine-coated nanodrugs for effective photothermal- and chemo-synergistic therapies against lung cancer

Light-responsive AIE Nanoparticles with Cytosolic Drug Release to Overcome Drug Resistance in Cancer Cells

Mitochondrial Targeted Doxorubicin-Triphenylphosphonium Delivered by Hyaluronic Acid Modified and pH Responsive Nanocarriers to Breast Tumor: in Vitro and in Vivo Studies.

Overcoming Drug Resistance with Functional Mesoporous Titanium Dioxide Nanoparticles Combining Targeting, Drug Delivery and Photodynamic Therapy

Amphiphilic tumor-targeting chimeric peptide-based drug self-delivery nanomicelles for overcoming drug resistance in cancer by synergistic chemo-photodynamic therapy

Enhanced Reactive Oxygen Species Generation by Mitochondria Targeting of Anti-cancer Drug to Overcome Tumor Multidrug Resistance.

Reversing Chemotherapy Resistance by a Synergy between Lysosomal pH-Activated Mitochondrial Drug Delivery and Erlotinib-Mediated Drug Efflux Inhibition